Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publicado em
- 1 out 2025
- Citações
- 6
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial
Alexej Ballhausen, Susanna Swoboda, David Horst, Stefan Fruehauf, Ullrich Graeven, Lothar Müller, Tanja Trarbach, Ludwig Fischer von Weikersthal, Eray Goekkurt, Volker Heinemann et al.
Descritores MeSH
- Colorectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- ras Proteins
- Tumor Microenvironment
- Biomarkers, Tumor
- Humans
- Male
- Middle Aged
- Prognosis
- Lymphocytes, Tumor-Infiltrating
Veja também
Estudos relacionados
- Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer
- Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
- Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
- First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial